42.0.0.26 – Redirect Fix (Removed pre-redirect output)
DEBUG LOG – klik om te openen
=== VARIABELEN ===
Array
(
[defid] => VWS-WOO-08-1246215
[request_id] =>
)
=== SQL LOG ===
Geen SQL queries.
Huidig document record
Array
(
[id] => 38a9e638-366d-4ff4-9c12-0fd365da667c
[Document ID] => 1246215
[Document naam] => FW: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
[Bestandsnaam] =>
[Beoordeling] =>
[Beoordelingsgrond] =>
[Toelichting] =>
[Publieke link] =>
[Locatie open.minvws.nl] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1246215
[Opgeschort] =>
[Definitief ID] => VWS-WOO-08-1246215
[Status] =>
[FromFile] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
[DocumentPublicationDate] => 22 maart 2021
[DocumentStatusCheckedDate] =>
[DocumentStatusCheckedResult] =>
[SourceFileType] =>
[Tags] =>
[Besluit] =>
[ModifiedDate] => 2025-09-22 08:11:03
[DeletedDate] =>
[BesluitURL] =>
[CreatedDate] => 2025-06-19 18:31:59
[DocumentDownloadLink] =>
[DigestLaatsteControleDatum] => 2025-09-22 08:11:03
)
Document: VWS-WOO-08-1246215
Klik om te vergroten
Document correcties
Geregistreerde datum: 20210322
Geregistreerde documentnaam: FW: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
Document attributen
| Tag | Waarde | Datum |
|---|---|---|
| About_Gelakte gegevens | 5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten | 2025-09-01 19:57:57 |
| About_Gelakte gegevens_linkhref_2 | mailto:DienstpostbusDatalekkenDoo@minvws.nl | 2025-09-01 19:57:57 |
| DocumentDownload_linkname | Download (pdf, 495.95 KB) | 2025-07-10 19:48:28 |
| DocumentDownload_linkhref | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/document/1eec1b43-38bc-60a6-ab11-bb3705657b16 | 2025-07-10 19:48:28 |
| DocumentDownload_proposed_filename (lokale kopie) | VWS-WOO-08-1246215.pdf | 2025-07-10 19:48:28 |
| document_SectionDownloadButton | 1 | 2025-07-10 19:48:28 |
| document_SectionHistory | 1 | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkhref_2 | mailto:_dienstpostbusWoo-corona-ondersteuning@minvws.nl?subject=Opmerking over FW: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis (documentnummer 1eec1b43-38bc-60a6-ab11-bb3705657b16) | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkname_2 | Laat het ons weten | 2025-06-22 23:45:23 |
| document_SectionLinked | 1 | 2025-06-22 23:45:23 |
| document_SectionRequest | 1 | 2025-06-22 23:45:23 |
| Request_Onderdeel van | Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 2021 | 2025-06-22 23:45:23 |
| Request_Onderdeel van_linkhref_1 | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo | 2025-06-22 23:45:23 |
| Request_Onderdeel van_linkname_1 | Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 2021 | 2025-06-22 23:45:23 |
| Request_Samenvatting verzoek | De minister van Volksgezondheid, Welzijn en Sport heeft op 23 november 2023 een besluit genomen op verzoeken in het kader van de Wet open overheid. Het besluit betreft openbaarmaking van documenten die betrekking hebben op informatie aangaande Vaccinaties & Medicatie maart 2021. | 2025-06-22 23:45:23 |
| Request_Periode | Maart 2021 | 2025-06-22 23:45:23 |
| Request_Type besluit | Woo-besluit | 2025-06-22 23:45:23 |
| Request_Datum besluit | 23 november 2023 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking | 15.961 documenten, 29.047 pagina's Inventarislijst | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_documenten | 15.961 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_paginas | 29.047 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_linkhref_1 | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/inventory | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_linkname_1 | Inventarislijst | 2025-06-22 23:45:23 |
| document_documentName | FW: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis | 2025-06-22 23:45:23 |
| document_documentType | E-mailbericht | 2025-06-22 23:45:23 |
| document_documentPublicationDate | 2021-03-22 | 2025-06-22 23:45:23 |
| document_documentNumber | VWS-WOO-08-1246215 | 2025-06-22 23:45:23 |
| document_SectionDownloadButton | 0 | 2025-06-22 23:45:23 |
| document_SectionHTMLDataDivs | 4 | 2025-06-22 23:45:23 |
| document_SectionAbout | 1 | 2025-06-22 23:45:23 |
| About_Datum document | 22 maart 2021 | 2025-06-22 23:45:23 |
| About_Type bronbestand | E-mailbericht, 3 pagina's | 2025-06-22 23:45:23 |
| About_Type bronbestand_paginas | 3 | 2025-06-22 23:45:23 |
| About_Download als | PDF (495.95 KB) | 2025-06-22 23:45:23 |
| About_Documentnummer | 1246215 | 2025-06-22 23:45:23 |
| About_Beoordeling | Gedeeltelijke openbaarmaking | 2025-06-22 23:45:23 |
| About_Gelakte gegevens | 5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten. | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkhref_1 | https://wetten.overheid.nl/BWBR0045754/2022-08-01#Hoofdstuk5 | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkname_1 | 5.1.2e Eerbiediging van de persoonlijke levenssfeer | 2025-06-22 23:45:23 |
| History Actie_2 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_3 | 30 mei 2024 18:36 | 2025-06-21 06:28:06 |
| History Actie_3 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_4 | 30 mei 2024 18:22 | 2025-06-21 06:28:06 |
| History Actie_4 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_5 | 30 mei 2024 16:51 | 2025-06-21 06:28:06 |
| History Actie_5 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_6 | 30 mei 2024 16:37 | 2025-06-21 06:28:06 |
| History Actie_6 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_7 | 30 mei 2024 15:04 | 2025-06-21 06:28:06 |
| History Actie_7 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_8 | 30 mei 2024 14:51 | 2025-06-21 06:28:06 |
| History Actie_8 | Bronbestand toegevoegd (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_2 | 30 mei 2024 19:15 | 2025-06-21 06:28:06 |
| History Actie_1 | Bronbestand vervangen (pdf, 495.95 KB) | 2025-06-21 06:28:06 |
| History Datum_1 | 30 mei 2024 19:19 | 2025-06-21 06:28:06 |
Archiefversies (6 rijen)
Archiefrij 1 — 2025-09-07 17:26:29
fromFile: folder_import
fromFilePath: /volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-08-1246215.pdf
documentName: VWS-WOO-08-1246215.pdf
documentType: pdf
documentCompressedSize: 0
documentSize: 507851
documentCompressRatio: 0
documentDateModified: 2025-09-07 17:26:29
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-07 17:26:29
lastSeen: 2025-09-07 17:26:29
text: 1246215
To: @rivm.nl]
Cc: @rivm.n(];IEEEEE@rivm.nl]
From:
Sent: Mon 3/22/2021 10:47:28 AM
Subject: FW: AstraZeneca-AZD1222 USPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 10:47:29 AM
Ook voor jou puur tkn. Als we namorgen een scenario sc...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 31211e1dd91064cabbb638b440039d008eda50f69b928b72bd1fa5c398a512a0
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: folder_import_49259_45f4a87de9eb9718a96d8296a3838459
textDigestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1246215
Archiefrij 2 — 2025-09-04 17:12:23
fromFile: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
documentName: VWS-WOO-08-1246215.pdf
documentType: pdf
documentCompressedSize: 203236
documentSize: 507851
documentCompressRatio: 40.01882441897328
documentDateModified: 2025-05-01 20:33:18
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:12:23
lastSeen: 2025-09-04 17:12:23
text: 1246215 To: @rivm.nl] @rivm.n(]; IEE Cc: EEE @rivm.nl] From: Sent: Mon 3/22/2021 10:47:28 AM FW: AstraZeneca AZD1222 US Phase lll trial met primary efficacy endpoint in preventing COVID-19 at interim analysis Subject: - Received: Mon 3/22/2021 10:47:29 AM Ook voo...
noTextDate: leeg!
ocrText: 1227720 Artikel ArtikeIType, ArtikelFarmaceut ArtikelDescription ArtikelCategorie ArtikelAantal ArtikelEenheid, ArtikelHoeveelheid, ArtikelHoeveelheid Flacons,ArtikelHoeveelheidDosesPerTray ArtikelHoeveelheidDoses, ArtikelAfnemer ArtikelAfnemerGroep, ArtikelAfgiftedatum , ArtikelStatus, ArtikelAfze...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 31211e1dd91064cabbb638b440039d008eda50f69b928b72bd1fa5c398a512a0
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:20.178639+00
Id: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip_2292
textDigestSHA256: 74ccee5e080fef7ddb69ddd2d671fb3e93e102bb59ac66c05002891c9453e698
ocrTextDigestSHA256: cbb318e36bc801b51a4e835f266ccf9e2f2591f7587882f9cceab6e8131f83fb
extractedId: VWS-WOO-08-1246215
Archiefrij 3 — 2025-09-04 17:10:20
fromFile: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
documentName: VWS-WOO-08-1246215.pdf
documentType: pdf
documentCompressedSize: 203236
documentSize: 507851
documentCompressRatio: 40.01882441897328
documentDateModified: 2025-05-01 20:33:18
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:10:20
lastSeen: 2025-09-04 17:10:20
text: 1246215 To: @rivm.nl] @rivm.n(]; IEE Cc: EEE @rivm.nl] From: Sent: Mon 3/22/2021 10:47:28 AM FW: AstraZeneca AZD1222 US Phase lll trial met primary efficacy endpoint in preventing COVID-19 at interim analysis Subject: - Received: Mon 3/22/2021 10:47:29 AM Ook voo...
noTextDate: leeg!
ocrText: isoweek-2021 isoweek-2022 |Ct-waarde 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 31211e1dd91064cabbb638b440039d008eda50f69b928b72bd1fa5c398a512a0
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:20.178639+00
Id: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip_2292
textDigestSHA256: 74ccee5e080fef7ddb69ddd2d671fb3e93e102bb59ac66c05002891c9453e698
ocrTextDigestSHA256: 34ea7743594f08b217c2e155c1f4035ef17e172d69327d310aa73507055b967b
extractedId: VWS-WOO-08-1246215
Archiefrij 4 — 2025-03-18 09:30:26
fromFile: 2024.075-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2024.075-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1246215-FW_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 202578
documentSize: 507851
documentCompressRatio: 39.88925885742078
documentDateModified: 2024-10-25 13:30:30
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-03-18 09:30:26
lastSeen: 2025-03-18 09:30:26
text: 1246215
To: @rivm.nl]
Cc: @rivm.n(];IEEEEE@rivm.nl]
From:
Sent: Mon 3/22/2021 10:47:28 AM
Subject: FW: AstraZeneca-AZD1222 USPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 10:47:29 AM
Ook voor jou puur tkn. Als we namorgen een scenario sc...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:20.178639+00
Id: 355357
textDigestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1246215
Archiefrij 5 — 2025-02-27 09:25:06
fromFile: 2022.252-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2022.252-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1246215-FW_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 202578
documentSize: 507851
documentCompressRatio: 39.88925885742078
documentDateModified: 2024-10-25 13:30:30
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-27 09:25:06
lastSeen: 2025-02-27 09:25:06
text: 1246215
To: @rivm.nl]
Cc: @rivm.n(];IEEEEE@rivm.nl]
From:
Sent: Mon 3/22/2021 10:47:28 AM
Subject: FW: AstraZeneca-AZD1222 USPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 10:47:29 AM
Ook voor jou puur tkn. Als we namorgen een scenario sc...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 12, "email": "@rivm.nl", "context": "1246215 To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From:"}, {"position": 36, "email": "IEEEEE@rivm.nl", "context": "To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From: Sent: Mon"}]
documentMailAdresses: [{"position": 12, "email": "@rivm.nl", "context": "1246215 To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From:"}, {"position": 36, "email": "IEEEEE@rivm.nl", "context": "To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From: Sent: Mon"}]
digestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 268527
textDigestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1246215
Archiefrij 6 — 2025-02-18 12:18:04
fromFile: Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
documentName: VWS-WOO-08-1246215-FW_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 202578
documentSize: 507851
documentCompressRatio: 39.88925885742078
documentDateModified: 2024-10-25 13:30:30
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-18 12:18:04
lastSeen: 2025-02-18 12:18:04
text: 1246215
To: @rivm.nl]
Cc: @rivm.n(];IEEEEE@rivm.nl]
From:
Sent: Mon 3/22/2021 10:47:28 AM
Subject: FW: AstraZeneca-AZD1222 USPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 10:47:29 AM
Ook voor jou puur tkn. Als we namorgen een scenario sc...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 12, "email": "@rivm.nl", "context": "1246215 To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From:"}, {"position": 36, "email": "IEEEEE@rivm.nl", "context": "To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From: Sent: Mon"}]
documentMailAdresses: [{"position": 12, "email": "@rivm.nl", "context": "1246215 To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From:"}, {"position": 36, "email": "IEEEEE@rivm.nl", "context": "To: @rivm.nl] Cc: @rivm.n(];IEEEEE@rivm.nl] From: Sent: Mon"}]
digestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
documentDate: leeg!
ModifiedDate: 2025-12-10 19:40:42.137456+00
Id: 57663
textDigestSHA256: bbb7d2be3eb6bfbf500532adf8814543d367fc5d35d53878ec5808c8cf689ab4
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1246215
(dit is ook een speeltuin)